Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        11-20 of 60 results for 'Princess margaret hospital medical research foundation'

        Refine search

        AussieRett

        AussieRett Study Aims Contact Us To monitor patterns of Rett syndrome occurrence. To develop and maintain an ongoing data collection which will ...

        Research

        New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment

        We provide evidence that targeting leukemia-induced bone loss is a therapeutic strategy for pre-B ALL ...

        Research

        Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin

        The prognosis for high-risk childhood acute leukaemias remains dismal and established treatment protocols often cause long-term side effects in survivors. This study aims to identify more effective and safer therapeutics for these patients. ...

        Research

        Connective tissue growth factor is expressed in bone marrow stromal cells and promotes interleukin-7-dependent B lymphopoiesis

        Hematopoiesis occurs in a complex bone marrow microenvironment in which bone marrow stromal cells provide critical support to the process through direct cell... ...

        Research

        Evaluating the use and effectiveness of passive immunization in reducing RSV-associated morbidity in high risk infants

        Hannah Tom Moore Snelling HC T OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Program Head, Infection and Vaccines Head, ...

        Research

        Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

        Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL. ...

        Research

        Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

        Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL. ...

        Research

        Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy

        Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. ...

        Research

        Multi-centre, multi-disciplinary study using a systems biology approach to investigate immunomodulation in children with acute wheeze

        Ingrid Pat Laing Holt IL PG BSc PhD PhD, DSc, FRCPath, FRCPI, FAA Head, Children's Respiratory Science Emeritus Honorary Researcher 6319 1828 ...

        News & Events

        Premmie twins defy the odds

        When Samuel and James Considine were born in October 2003, perilously close to what the medical world describes as the limit of viability, each weighed just 700 grams and could fit into the palm of their father’s hand. ...

        Page 2 of 6